Yes, warfarin and amiodarone can be taken together, but this combination is documented as a major-severity drug interaction that requires close monitoring. When amiodarone is added to warfarin therapy, amiodarone inhibits the enzyme that breaks down warfarin in your body, causing warfarin levels to rise and increasing your bleeding risk. Your INR (International Normalized Ratio, a measure of blood-clotting time) will likely need to be checked more frequently, and your warfarin dose may need to be adjusted downward to maintain safety.
According to the FDA-derived source record from NLM/RxNorm data, amiodarone is classified as a CYP2C9 inhibitor that increases warfarin effect and INR and requires close INR monitoring. The interaction is rated as major severity, meaning it carries significant clinical risk and cannot be ignored.
This interaction is well-documented in U.S. FDA drug labeling and is a standard consideration whenever these two medications are prescribed together. The source record does not specify additional details about incidence rates or exact INR elevation ranges; however, the major-severity classification reflects that this is a predictable and clinically important interaction requiring active management.
Warfarin is an anticoagulant (blood thinner) prescribed to reduce clot formation in conditions such as atrial fibrillation, mechanical heart valves, or venous thromboembolism. It works by interfering with the liver's use of vitamin K to produce clotting factors. The balance is delicate: too little warfarin and clots may form; too much and bleeding risk rises sharply.
Warfarin's effect is monitored using the INR, a standardized blood test that tells you how much longer your blood takes to clot compared to normal. A typical INR target for most patients is 2 to 3, meaning blood clots 2 to 3 times slower than it should.
Amiodarone is a potent antiarrhythmic medication prescribed for serious heart rhythm disorders, including atrial fibrillation and certain types of ventricular arrhythmia. It works by slowing electrical conduction in the heart, helping restore a normal rhythm.
The source record identifies the interaction mechanism as CYP2C9 inhibition. CYP2C9 is an enzyme (a type of protein in your liver) that metabolizes (breaks down) warfarin. When amiodarone inhibits this enzyme, warfarin is broken down more slowly, causing it to accumulate in your bloodstream. Higher warfarin levels mean stronger anticoagulation—which can push your INR above the target range and increase your risk of bleeding.
This is a documented pharmacological fact supported by FDA labeling and is the reason this pairing is classified as major-severity.
When any drug slows the metabolism of warfarin, the result is predictable: INR increases. An INR that climbs too high significantly raises the risk of major bleeding events (gastrointestinal bleeding, intracranial bleeding, or other serious bleeds). This is why close monitoring is non-negotiable when amiodarone is added to warfarin therapy.
Conversely, if amiodarone is withdrawn after the warfarin dose has been lowered to compensate for the interaction, INR can fall back toward subtherapeutic levels, risking clot formation. This is why discontinuation of amiodarone also requires careful INR follow-up and possible dose adjustment.
All patients taking both warfarin and amiodarone should be aware of this interaction. However, some general considerations apply:
These observations are general pharmacological principles and do not replace personalized assessment by your healthcare team. Your pharmacist or physician can evaluate your specific situation, including your age, kidney and liver function, and other medications.
Suppose a patient has been on warfarin 5 mg daily for six months with a stable INR of 2.5. The patient develops atrial fibrillation with a rapid ventricular rate, and the physician prescribes amiodarone 400 mg daily for rhythm control. Within the first week, the patient's INR begins to climb (perhaps to 3.2 or 3.5) because amiodarone is inhibiting CYP2C9 and warfarin is accumulating. The physician would order more frequent INR checks—possibly within 3 to 5 days—and may reduce the warfarin dose to 4 mg daily or lower to bring the INR back to the target range. Over the following weeks, as amiodarone reaches steady state in the body, INR monitoring continues at regular intervals (perhaps weekly or every 2 weeks) until it is stable again. This example illustrates why baseline INR and frequent rechecking are essential whenever amiodarone is introduced.
Conversely, if a patient on both warfarin 4 mg and amiodarone decides to stop amiodarone (because the arrhythmia has resolved or side effects are intolerable), the CYP2C9 inhibition gradually decreases. Warfarin is now metabolized more quickly, and INR begins to fall. If the warfarin dose is not adjusted upward, INR may drop below the therapeutic target, increasing clot risk. Close INR monitoring after amiodarone discontinuation is equally important and typically continues for several weeks until a new stable INR plateau is reached.
If you are prescribed or are currently taking both warfarin and amiodarone, consider these questions and discussion points with your healthcare provider:
These questions are meant to prompt informed conversation with your team, not to replace their judgment. Do not change your warfarin dose, skip doses, or stop either medication without explicit instruction from your physician or pharmacist.
This article explains the documented interaction between warfarin and amiodarone based on FDA and NLM/RxNorm source material. It is educational only and does not replace personalized medical advice. If you are taking warfarin, amiodarone, or both, check your complete medication list using the tool at checkdruginteractions.com to identify other potential interactions. Always confirm medication decisions—including doses, timing, and any changes—with your pharmacist or physician before acting on them. Your healthcare team has access to your full medical history and can provide guidance tailored to your individual needs.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
A major drug interaction between methotrexate and aspirin can increase methotrexate levels. Learn what this means and how to discuss it w...
Metronidazole increases warfarin's blood-thinning effect by inhibiting CYP2C9. This is a major interaction requiring close INR monitoring.
Gemfibrozil is contraindicated with repaglinide due to an 8.1-fold increase in drug exposure via CYP2C8 inhibition. Learn what this means...